Bionime Corporation

4737.TW

4737.TWBionime Corporation TW flag

Taipei Exchange

74.80

TWD

-0.60

(-0.80%)

-2.22EPS

-33.69P/E

4.57BMarket Cap

Aug 07Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

TW0004737002

Return %

Stock

S&P500

7.47

12.07

1.91

62.30

-5.08

98.08

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	32.11	35.52	34.36	31.13	27.43	30.66	34.94	37.79	28.2	30.79	36.52	28.89	31.72	32.14
Basic EPS, GAAP	0.74	2.05	1.22	1.91	2.82	2.52	2.23	1.85	1.06	1.45	1.5	0.1	-2.09	-2.22
Free Cash Flow per Basic Share	-22.87	-7.91	6.83	1.22	6.64	-1.57	-0.82	4.65	-1.33	-0.25	-2.82	-3.92	-5.14	-3.44
Dividend per Share	3.54	0.8	1.76	0.94	2	4.06	4.14	2	2.01	2.07	2	2.1	2	- -
Book Value per Share	11.78	13.22	14.23	15.51	14.06	11.66	14.27	14.86	13.81	14.37	12.77	12.52	10.26	10.1
Tangible Book Value per Share	21.13	23.44	29.63	48.66	40.51	34.8	34.55	34.74	31.52	28.86	26	22.21	18.25	18.07
Basic Weighted Avg Shares	45	44	44	52	63	59	57	57	59	60	61	61	61	61
Sales/Revenue/Turnover	1,435	1,561	1,525	1,610	1,740	1,820	2,007	2,173	1,669	1,850	2,211	1,756	1,934	1,947
Operating Margin (%)	4.87	9.28	9.79	11.79	14.85	13.9	11.92	7.66	2.66	2.96	7.28	-2.84	-6.67	-7.89
Depreciation Expense	99	105	148	153	158	146	151	164	163	155	153	163	183	187
Net Income, GAAP	33	90	54	99	179	150	128	106	62	87	91	6	-127	-135
Effective Tax Rate (%)	48.47	27.52	36.77	19.83	16.43	21.03	21.04	20.7	- -	- -	- -	- -	- -	- -
Profit Margin (%)	2.32	5.76	3.56	6.14	10.27	8.22	6.38	4.89	3.74	4.73	4.12	0.35	-6.58	-6.92
Working Capital	194	124	-65	850	482	-70	289	214	216	60	226	8	-537	-326
LT Debt	1,923	2,144	1,710	1,330	795	738	1,115	976	1,173	1,157	1,491	1,697	1,579	1,809
Total Equity	993	1,071	1,347	2,542	2,587	2,078	1,993	2,047	2,071	2,076	2,081	1,993	1,889	1,891
Return on Invested Capital (%)	1.23	2.75	2.22	3.58	5.12	4.9	4.68	3.28	- -	- -	- -	- -	- -	- -
Return on Capital (%)	1.63	3.2	2.63	4.82	7.97	6.69	5.5	4.64	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	5.65	16.24	8.96	13.78	21.11	18.88	16.93	12.69	7.47	10.4	11.12	0.81	-18.36	-19.81

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	3.35%	-0.65%	10.15%
Net Income, GAAP	-212.41%	-447.84%	-2,148.9%
Free Cash Flow	55.57%	181.95%	31.66%
Total Cash Common Dividend	16.76%	1.29%	-4.45%
Total Equity	6.16%	-1.56%	-5.23%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Chun-Mu Huang
Full Time Employees: 1,111
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Address: No. 100, Daqing Street Taichung Taiwan, Province of China 40242
IPO Date: Dec 23, 2010
Website: bionime.com
Similar Companies: Fisher & Paykel Healthcare Corporation Limited (FSPKF)
Innovative Eyewear, Inc. (LUCYW)
SDI Limited (SDI.AX)
Sharps Technology, Inc. (STSS)
TINAVI Medical Technologies Co., Ltd. (688277.SS)
Tofflon Science and Technology Group Co., Ltd. (300171.SZ)
Business: Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.

	Sep'24	Dec'24	Mar'25
Total Current Assets	1,648	1,774	1,678
Accounts Receivable, Net	568	666	565
Cash, Cash Equivalents & STI	388	383	404
Inventories	556	571	611
Total Current Liabilities	1,968	2,311	2,004
Payables & Accruals	- -	- -	- -
ST Debt	1,215	1,587	1,289
Deferred Revenue	- -	- -	- -

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	32.11	35.52	34.36	31.13	27.43	30.66	34.94	37.79	28.2	30.79	36.52	28.89	31.72	32.14
Basic EPS, GAAP	0.74	2.05	1.22	1.91	2.82	2.52	2.23	1.85	1.06	1.45	1.5	0.1	-2.09	-2.22
Free Cash Flow per Basic Share	-22.87	-7.91	6.83	1.22	6.64	-1.57	-0.82	4.65	-1.33	-0.25	-2.82	-3.92	-5.14	-3.44
Dividend per Share	3.54	0.8	1.76	0.94	2	4.06	4.14	2	2.01	2.07	2	2.1	2	- -
Book Value per Share	11.78	13.22	14.23	15.51	14.06	11.66	14.27	14.86	13.81	14.37	12.77	12.52	10.26	10.1
Tangible Book Value per Share	21.13	23.44	29.63	48.66	40.51	34.8	34.55	34.74	31.52	28.86	26	22.21	18.25	18.07
Basic Weighted Avg Shares	45	44	44	52	63	59	57	57	59	60	61	61	61	61
Sales/Revenue/Turnover	1,435	1,561	1,525	1,610	1,740	1,820	2,007	2,173	1,669	1,850	2,211	1,756	1,934	1,947
Operating Margin (%)	4.87	9.28	9.79	11.79	14.85	13.9	11.92	7.66	2.66	2.96	7.28	-2.84	-6.67	-7.89
Depreciation Expense	99	105	148	153	158	146	151	164	163	155	153	163	183	187
Net Income, GAAP	33	90	54	99	179	150	128	106	62	87	91	6	-127	-135
Effective Tax Rate (%)	48.47	27.52	36.77	19.83	16.43	21.03	21.04	20.7	- -	- -	- -	- -	- -	- -
Profit Margin (%)	2.32	5.76	3.56	6.14	10.27	8.22	6.38	4.89	3.74	4.73	4.12	0.35	-6.58	-6.92
Working Capital	194	124	-65	850	482	-70	289	214	216	60	226	8	-537	-326
LT Debt	1,923	2,144	1,710	1,330	795	738	1,115	976	1,173	1,157	1,491	1,697	1,579	1,809
Total Equity	993	1,071	1,347	2,542	2,587	2,078	1,993	2,047	2,071	2,076	2,081	1,993	1,889	1,891
Return on Invested Capital (%)	1.23	2.75	2.22	3.58	5.12	4.9	4.68	3.28	- -	- -	- -	- -	- -	- -
Return on Capital (%)	1.63	3.2	2.63	4.82	7.97	6.69	5.5	4.64	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	5.65	16.24	8.96	13.78	21.11	18.88	16.93	12.69	7.47	10.4	11.12	0.81	-18.36	-19.81

Year	Q1	Q2	Q3	Q4	FY
2023	415	426	425	490	1,756
2024	468	475	488	502	1,934
2025	481	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	-0.09	0.17	-0.17	- -	0.1
2024	-0.08	-0.59	-0.88	- -	-2.09
2025	-0.21	- -	- -	- -	- -

	Sep'24	Dec'24	Mar'25
ST Debt	1,215	1,587	1,289
LT Borrowings	1,733	1,578	1,809
LT Finance Leases	3	1	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	61	61	61
Market Capitalization	4,258	3,987	3,756

Bionime Corporation

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year